Open AccessPersonalized chemotherapy in clear cell adenocarcinoma of the urethra: A case report
Author(s) -
Lisa B. E. Shields,
Arash Rezazadeh Kalebasty
Publication year - 2020
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v11.i4.243
Subject(s) - medicine , clear cell adenocarcinoma , urethra , chemotherapy , bevacizumab , adenocarcinoma , radiology , cancer , urology , oncology , surgery
Clear cell adenocarcinoma of the urethra is a rare type of aggressive cancer with a poor prognosis. Clear cell carcinoma of the urethra represents less than 0.02% of all malignancies in women. Adenocarcinomas account for 10% of female urethral carcinomas, of which 40% are the clear cell variant. Determining the presence or absence of certain mutations through genetic testing may predict whether a patient with cancer may benefit from a particular chemotherapy regimen.